JP2014518883A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014518883A5 JP2014518883A5 JP2014512833A JP2014512833A JP2014518883A5 JP 2014518883 A5 JP2014518883 A5 JP 2014518883A5 JP 2014512833 A JP2014512833 A JP 2014512833A JP 2014512833 A JP2014512833 A JP 2014512833A JP 2014518883 A5 JP2014518883 A5 JP 2014518883A5
- Authority
- JP
- Japan
- Prior art keywords
- tl1a
- monoclonal antibody
- clone
- agent
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161488671P | 2011-05-20 | 2011-05-20 | |
| US61/488,671 | 2011-05-20 | ||
| PCT/US2012/028926 WO2012161856A1 (en) | 2011-05-20 | 2012-03-13 | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014518883A JP2014518883A (ja) | 2014-08-07 |
| JP2014518883A5 true JP2014518883A5 (enExample) | 2015-03-19 |
Family
ID=47217582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014512833A Withdrawn JP2014518883A (ja) | 2011-05-20 | 2012-03-13 | Ｔ細胞媒介疾病の病態を改善させるためのｔｌ１ａ−ｄｒ３相互作用の遮断及びその抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9068003B2 (enExample) |
| EP (1) | EP2709664A4 (enExample) |
| JP (1) | JP2014518883A (enExample) |
| KR (1) | KR20140104344A (enExample) |
| AU (1) | AU2012259312A1 (enExample) |
| CA (1) | CA2836898A1 (enExample) |
| MX (1) | MX2013013329A (enExample) |
| WO (1) | WO2012161856A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2536086C (en) * | 2003-08-20 | 2013-03-19 | University Of Miami | Inhibition of dr3 in the treatment of allergic lung inflammation |
| BRPI0617057A2 (pt) | 2005-08-30 | 2011-07-12 | Univ Miami | anticorpo isolado, toxina especìfica para receptor de fator de necrose tumoral 25 (tnfr25), método para ativar o receptor de fator de necrose tumoral 25 (tnfr25), método para inibir a sinalização do receptor de fator de necrose tumoral 25 (tnfr25) numa célula, vacina antitumoral, método para imunizar um paciente contra tumor, método para tratar cáncer num paciente, método para tratar e/ou prevenir inflamação intestinal, composição terapêutica para a facilitação de um transplante de órgão, método para transplantar um tecido de um doador para um hospedeiro, método para inibir a expressão clonal de uma população de células t cd8 cognatas, método para tratar e/ou prevenir inflamação pulmonar, antagonista de tnfr25 isolado, composição e vetor de expressão |
| US9896511B2 (en) | 2007-01-10 | 2018-02-20 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies |
| WO2010062960A2 (en) | 2008-11-26 | 2010-06-03 | Cedars-Sinai Medical Center | METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE |
| DK2462165T3 (en) | 2009-08-03 | 2016-08-29 | Univ Miami | Method for in vivo proliferation of regulatory T cells |
| US8766034B2 (en) | 2010-09-22 | 2014-07-01 | Cedars-Sinai Medical Center | TL1A model of inflammation fibrosis and autoimmunity |
| MX2014003689A (es) | 2011-09-30 | 2014-12-05 | Teva Pharmaceuticals Australia Pty Ltd | Anticuerpos contra tl1a y sus usos. |
| EA201591153A1 (ru) * | 2013-01-02 | 2016-01-29 | Гленмарк Фармасьютикалс С.А. | Антитела, связывающиеся с tl1a, и их применение |
| CA2897826C (en) | 2013-01-09 | 2022-09-27 | Taylor H. Schreiber | Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein |
| KR20230109779A (ko) | 2013-03-27 | 2023-07-20 | 세다르스-신나이 메디칼 센터 | Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전 |
| EP2996717A4 (en) * | 2013-05-17 | 2016-11-23 | Cedars Sinai Medical Center | DIFFERENT EFFECTS OF IFN-GAMMA AND IL-17 ON TL1A-MODULATED INFLAMMATION AND FIBROSIS |
| CN105358713B (zh) * | 2013-05-17 | 2020-02-28 | 雪松-西奈医学中心 | 与克罗恩病相关的tnfsf15和dcr3的变体 |
| EP4105236A1 (en) | 2013-07-19 | 2022-12-21 | Cedars-Sinai Medical Center | Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease |
| WO2015035261A1 (en) * | 2013-09-06 | 2015-03-12 | Cedars-Sinai Medical Center | Systems, devices and methods for anti-tl1a therapy |
| EP3068801A1 (en) * | 2013-11-13 | 2016-09-21 | Pfizer Inc. | Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof |
| CA2947255A1 (en) | 2014-04-28 | 2015-11-05 | The National Institute for Biotechnology in the Negev Ltd. | Variants of dr3 and use thereof |
| CA2994719A1 (en) | 2015-08-21 | 2017-03-02 | The Children's Hospital Of Philadelphia | Methods of treating autoimmune conditions in patients with genetic variations in dcr3 or in a dcr3 network gene |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| US20180319889A1 (en) * | 2015-11-02 | 2018-11-08 | La Jolla Institute For Allergy & Immunology | Method and medicament for treating airway and/or lung diseases |
| CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| KR20180127416A (ko) | 2016-03-17 | 2018-11-28 | 세다르스-신나이 메디칼 센터 | Rnaset2를 통한 염증성 장 질환의 진단 방법 |
| CN109476698B (zh) | 2016-05-20 | 2023-10-17 | 西达-赛奈医疗中心 | 基于基因的炎性肠病诊断 |
| CN118240830A (zh) * | 2016-10-26 | 2024-06-25 | 西达-赛奈医疗中心 | 中和抗tl1a单克隆抗体 |
| CN112585165B8 (zh) | 2018-04-25 | 2025-02-14 | 普罗米修斯生物科学公司 | 优化的抗tl1a抗体 |
| CA3121167A1 (en) * | 2018-11-29 | 2020-06-04 | Cedars-Sinai Medical Center | Methods of stratifying and treating a sub-population of inflammatory bowel disease patients |
| CN114901311A (zh) | 2019-10-24 | 2022-08-12 | 普罗米修斯生物科学公司 | Tnf样配体1a（tl1a）的人源化抗体及其用途 |
| WO2021102433A1 (en) * | 2019-11-22 | 2021-05-27 | The Research Foundation For The State University Of New York | Compositions and methods for use in type 1 diabetes |
| EP4501966A4 (en) * | 2022-06-17 | 2025-10-22 | Selecxine Inc | ANTIBODY SPECIFICALLY BINDING TO HUMAN DR3 AND ITS USE |
| IL324671A (en) | 2023-05-17 | 2026-01-01 | Genentech Inc | Anti-tl1a antibody therapeutic methods |
| CN120399074B (zh) * | 2023-06-02 | 2025-12-30 | 安徽金百奥生物科技有限公司 | 一种与人dr3胞外域高亲和力的纳米抗体 |
| IL325993A (en) | 2023-08-11 | 2026-03-01 | Paragon Therapeutics Inc | TL1A binding proteins and methods of use |
| US12473370B2 (en) | 2023-10-03 | 2025-11-18 | Absci Corporation | TL1A associated antibody compositions and methods of use |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0400047B1 (en) | 1988-02-05 | 1997-04-23 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
| JP3082204B2 (ja) | 1988-09-01 | 2000-08-28 | ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ | 両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス |
| US5162215A (en) | 1988-09-22 | 1992-11-10 | Amgen Inc. | Method of gene transfer into chickens and other avian species |
| US5168053A (en) | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| DK0638121T3 (da) | 1992-04-28 | 1996-08-12 | Univ Yale | Målrettet spaltning af RNA under anvendelse af eukaryotisk ribonuklease P og ekstern ledersekvens |
| DE69420137T2 (de) | 1993-06-03 | 1999-12-23 | Therapeutic Antibodies, Inc. | Herstellung von antikörperfragmenten |
| US5869248A (en) | 1994-03-07 | 1999-02-09 | Yale University | Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences |
| US7597886B2 (en) * | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| JP2000501284A (ja) | 1995-11-14 | 2000-02-08 | ビムラックス ホールディングズ，リミテッド | Ｒｎａ切断活性を有するキメラオリゴマー |
| KR0161881B1 (ko) | 1995-12-05 | 1999-02-01 | 문정환 | 메모리의 데이타 읽기회로 |
| WO1997033904A1 (en) | 1996-03-12 | 1997-09-18 | Human Genome Sciences, Inc. | Death domain containing receptors |
| US5955590A (en) | 1996-07-15 | 1999-09-21 | Worcester Foundation For Biomedical Research | Conjugates of minor groove DNA binders with antisense oligonucleotides |
| US6300483B1 (en) | 1997-06-19 | 2001-10-09 | Ribozyme Pharmaceuticals, Inc. | Compositions inducing cleavage of RNA motifs |
| JP2002510207A (ja) | 1997-06-19 | 2002-04-02 | リボザイム・ファーマシューティカルズ・インコーポレーテッド | 拡張された開裂ルールを有するハンマーヘッドリボザイム |
| EP1263788A2 (en) | 2000-02-11 | 2002-12-11 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function |
| KR100872437B1 (ko) | 2000-12-01 | 2008-12-05 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자 |
| CA2536086C (en) | 2003-08-20 | 2013-03-19 | University Of Miami | Inhibition of dr3 in the treatment of allergic lung inflammation |
| WO2006127900A2 (en) | 2005-05-25 | 2006-11-30 | Biogen Idec Ma Inc. | Tl1a in the treatment of disease |
| BRPI0617057A2 (pt) * | 2005-08-30 | 2011-07-12 | Univ Miami | anticorpo isolado, toxina especìfica para receptor de fator de necrose tumoral 25 (tnfr25), método para ativar o receptor de fator de necrose tumoral 25 (tnfr25), método para inibir a sinalização do receptor de fator de necrose tumoral 25 (tnfr25) numa célula, vacina antitumoral, método para imunizar um paciente contra tumor, método para tratar cáncer num paciente, método para tratar e/ou prevenir inflamação intestinal, composição terapêutica para a facilitação de um transplante de órgão, método para transplantar um tecido de um doador para um hospedeiro, método para inibir a expressão clonal de uma população de células t cd8 cognatas, método para tratar e/ou prevenir inflamação pulmonar, antagonista de tnfr25 isolado, composição e vetor de expressão |
| US20110217310A1 (en) * | 2007-01-10 | 2011-09-08 | Siegel Richard M | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology |
| MX2010005282A (es) * | 2007-11-13 | 2010-08-31 | Teva Pharma | Anticuerpos humanizados contra tl1a. |
-
2012
- 2012-03-13 AU AU2012259312A patent/AU2012259312A1/en not_active Abandoned
- 2012-03-13 US US13/419,203 patent/US9068003B2/en active Active
- 2012-03-13 MX MX2013013329A patent/MX2013013329A/es not_active Application Discontinuation
- 2012-03-13 EP EP12790157.7A patent/EP2709664A4/en not_active Withdrawn
- 2012-03-13 KR KR1020137033718A patent/KR20140104344A/ko not_active Withdrawn
- 2012-03-13 JP JP2014512833A patent/JP2014518883A/ja not_active Withdrawn
- 2012-03-13 CA CA2836898A patent/CA2836898A1/en not_active Abandoned
- 2012-03-13 WO PCT/US2012/028926 patent/WO2012161856A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Müller et al. | Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain | |
| JP2018121657A5 (enExample) | ||
| US10358493B2 (en) | Bispecific format suitable for use in high-through-put screening | |
| Igawa et al. | Reduced elimination of IgG antibodies by engineering the variable region | |
| US11286312B2 (en) | Multispecific antibodies | |
| JP2015214563A5 (enExample) | ||
| JP2017114866A5 (enExample) | ||
| JP2012012402A5 (enExample) | ||
| HRP20151227T1 (hr) | Sastavi i postupci uporabe za terapeutska protutijela | |
| JP2012501669A5 (enExample) | ||
| JP2012501670A5 (enExample) | ||
| JP2013539369A5 (enExample) | ||
| JP2012143232A5 (enExample) | ||
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| JP2011523550A5 (enExample) | ||
| RU2016123839A (ru) | Новые модуляторы и способы их применения | |
| JP2012520679A5 (enExample) | ||
| JP2020501532A5 (enExample) | ||
| RU2017134909A (ru) | Новая форма IL33, мутировавшие формы IL33, антитела, анализы и способы их применения | |
| JP2018502572A5 (enExample) | ||
| JP2017529067A5 (enExample) | ||
| JP2016026303A5 (enExample) | ||
| JP2016503412A5 (ja) | Ｉｌ−６アンタゴニストおよびその使用 | |
| TWI797124B (zh) | 抗干擾素-γ之抗體及其應用 | |
| JP2010533498A5 (enExample) |